News

Fourth NDA For Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Accepted By The Center For Drug Evaluation
On May 16, 2024, the CDE's official website announced that the Application would be reviewed via the priority review and approval process. This marks the fourth sac-TMT indication to go through the ...
Manila Bulletin1d
Turning every step into a stride toward Cervical Cancer elimination
In the battle against cervical cancer, every footstep matters. This May, they are taken with a purpose. As part of the ...
TipRanks on MSN1d
Sichuan Kelun-Biotech’s New Breast Cancer Treatment Application Accepted by NMPA
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) has provided an update. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Orion Oyj: Orion's collaborator, MSD, expands clinical development program for opevesostat to women's cancers
ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion's collaborator, MSD, expands clinical development program for opevesostat to women's cancers Orion's collaborator, ...
Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers
ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion’s collaborator, MSD, expands clinical development program for ...
pharmaphorum2d
Pfizer snaps up PD-1/VEGF drug from China's 3SBio
Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...